HITIQ has expanded its military research ambitions and added fresh funding during the September quarter, but the company ended the period with $658,242 in cash and estimated funding for only one quarter. Its US collaboration remains non-binding, leaving financing and commercial execution as the immediate tests.
- Non-binding US military research collaboration signed
- Cash balance of $658,242 after $1.453 million operating outflow
- Estimated funding available for approximately one quarter
- $1.5 million R&D facility drawn to $750,000 at 12% interest
- $1 million convertible note conversion reduced debt without raising cash
Cash Runway Tightens Despite New Funding
HITIQ Limited (ASX:HIQ) is pushing its PROTEQT technology towards military applications, but its September quarter numbers put the financing challenge in sharper relief. The concussion-management company finished the period with $658,242 in cash, while net operating cash outflows reached $1.453 million. Including $750,000 of undrawn finance, the Appendix 4C calculated approximately one quarter of available funding.
That runway estimate is based on the reported quarterly operating cash burn and does not include any future sales growth or additional capital. HITIQ said it expects cashflows to continue at the current level as sales increase and capital-management measures are implemented, and said it expects to secure further funding as required. Those are company expectations rather than committed funding sources.
US Defence Research Deal Remains Non-Binding
The most strategically ambitious development was an August Letter of Intent with the University of Southern Mississippi Sport and Tactical Athlete Research Lab and the University of Mississippi National Center for Tactical Readiness. The proposed work would use PROTEQT D-MAX and instrumented mouthguards to measure head-impact exposure and head-neck movement in military and tactical training, including possible firearms and special-operations applications.
HITIQ has also appointed former Australian Army Lieutenant Colonel Aaron Bell as Strategic Military Advisor. The company says he will assist with Defence engagement, procurement pathways, systems integration and military deployment requirements. But the research arrangement is not a procurement contract: study scope, funding, data and publication rights, and any future Cooperative Research and Development Agreements remain subject to separate agreements and approvals. The company has expressly stated that the collaboration does not represent committed revenue.
Debt Relief Came Without New Cash
HITIQ’s balance sheet received several forms of support during the quarter. Harmil Angel Investments converted $1 million of convertible notes, including associated interest, into 198.4 million shares. That reduces debt, but the conversion generated no cash proceeds, and a further note balance of $1.084 million remained outstanding at 30 September, with additional conversion at Harmil’s election.
The company also completed the second stage of its approximately $1.4 million placement, with shares issued at $0.007 each after shareholder approval. The filing’s Appendix 4C records $1.276 million of equity-security proceeds and $93,000 of transaction costs. The placement had been reported as a two-tranche capital raise two-tranche capital raise, with attaching options issued at the same exercise price and expiring in June 2027. Those options carry further piggyback options expiring in June 2029, but any future cash benefit depends on holders choosing to exercise.
R&D Facility Adds Liquidity and Interest Costs
HITIQ drew $750,000 from a new $1.5 million rolling R&D tax incentive facility with No Bull Health at 12% annual interest. A further $275,000 was drawn after quarter end. The facility was initially unsecured, although the company plans to seek shareholder approval for security over the arrangement. The new facility was previously reported as a $750,000 R&D loan drawdown $750,000 R&D loan drawdown, and sits alongside existing related-party facilities.
On 2 October, HITIQ said its previous R&D facility was repaid from a $1.066 million FY26 R&D tax incentive refund, with a $472,234 shortfall rolled into the new facility. The Victorian Government also provided $480,000 during July to support manufacturing and research activities. Together, those measures improved near-term liquidity, but they do not remove the underlying need to control expenditure or find additional funding.
Sport Sales Must Carry More Weight
Alongside its Defence and US expansion work, HITIQ is targeting the January sporting period through retail partners including Rebel, Chemist Warehouse, JB Hi-Fi and Amazon. It is also pursuing Australian community football partnerships and continuing US distribution and regulatory discussions. The next quarterly report will show whether those commercial efforts are translating into customer receipts: the company recorded only $2,889 from customers during the September quarter against $900,000 of staff costs and $755,000 of administration and corporate costs.
Bottom Line?
The Defence opportunity is still at research stage, while the financing clock is already running. The next meaningful test is whether sales and further funding arrive before the one-quarter runway narrows further.
Questions in the middle?
- Can HITIQ convert the US research collaboration into a funded study or formal military agreement?
- Will retail and community-sport partnerships lift customer receipts enough to reduce the current cash burn?
- What additional financing will be required if the reported operating outflow continues at a similar rate?